Essential cookies only by default. Analytics and error replays need your OK.
Efpeglenatide (LY3298176-class exendin-based GLP-1 receptor agonist)
An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky.
Prescription medication — not a dietary supplement
Efpeglenatide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Efpeglenatide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2019–2026 with a typical study size of 3,983 participants.
Based on 21 studies · 8 meta-analyses · 11 RCTs · 31,255 total participants
Study base
Strong study baseBy outcome
Every outcome below: Too few graded studies.
Efpeglenatide has unusually strong human cardiorenal evidence for an investigational drug — the pivotal AMPLITUDE-O trial showed reduced MACE and kidney-outcome events plus consistent HbA1c and weight benefit across its phase-2/3 program — but its proven benefits are metabolic/cardiorenal rather than a demonstrated longevity outcome, and it carries the full GLP-1-class GI side-effect burden, so it stays Emerging.
11 randomised trials
every one checked individually
Every randomised or controlled trial of Efpeglenatide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Jul 2026
No trials currently enrolling · 1 completed on ClinicalTrials.gov
1 of the completed trials have posted results
Registered trials show research momentum for Efpeglenatide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Efpeglenatide (development codes LY3298176 / HM11260C) is a long-acting, once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist developed by Hanmi Pharmaceutical and Sanofi.
It is mechanistically distinct from the dominant GLP-1 drugs in one important way: semaglutide, liraglutide, and dulaglutide are structurally modelled on human GLP-1, whereas efpeglenatide is EXENDIN-based — an exendin-4 (exenatide-lineage) backbone fused to a human IgG4 Fc fragment via a flexible linker (Hanmi's 'LAPSCOVERY' technology), which extends its half-life to support weekly dosing.
That distinction is the entire reason efpeglenatide matters scientifically: it was widely assumed that the cardiovascular benefit of GLP-1 agonists might be limited to the human-GLP-1-based agents, and AMPLITUDE-O was the trial that tested — and refuted — that hypothesis for an exendin-based drug.
Mechanistically efpeglenatide hits the same GLP-1 receptor cascade as the rest of the class: glucose-dependent insulin secretion with glucagon suppression in the pancreas (lowering HbA1c with low intrinsic hypoglycemia risk), central appetite suppression and satiety (driving weight loss), and slowed gastric emptying (blunting post-meal glucose and contributing to the dose-dependent nausea).
The clinical evidence is genuinely strong but the drug never reached market.
The pivotal trial is AMPLITUDE-O (Gerstein et al., N Engl J Med 2021; n=4,076), a randomized placebo-controlled cardiovascular-outcomes trial in people with type 2 diabetes who had a history of cardiovascular disease or kidney disease plus another risk factor: weekly efpeglenatide (4 or 6 mg) reduced the primary MACE outcome (nonfatal MI, nonfatal stroke, or cardiovascular/undetermined death) by 27% (HR 0.73, 95% CI 0.58-0.92; P=0.007 for superiority) and reduced a composite kidney outcome (worsening kidney function or new macroalbuminuria) by 32% (HR 0.68, 95% CI 0.57-0.79; P<0.001) — and a prespecified epidemiological analysis (Gerstein et al., Diabetes Obes Metab 2024) showed the cardiorenal benefit held across the full spectrum of baseline kidney disease (all interaction P≥0.26).
The earlier dose-finding and efficacy program established the metabolic signal: in early type 2 diabetes referenced to liraglutide (Rosenstock et al., Diabetes Care 2019; 'EXCEED 203', n≈254) efpeglenatide ≥1 mg lowered HbA1c by a placebo-adjusted 0.6-1.2% and was noninferior to open-label liraglutide at the 4 mg dose in an exploratory comparison; in obesity WITHOUT diabetes (Pratley et al., Diabetes Obes Metab 2019, phase-2, n=297) it produced placebo-adjusted weight loss of about 6.3-7.2 kg over 20 weeks; and AMPLITUDE-M (Frias et al., Diabetes Care 2022, phase-3 monotherapy) showed dose-dependent HbA1c reductions up to ~1.0% placebo-adjusted with weight loss.
A 2024 systematic review and meta-analysis (Qazi et al., 11 studies) pooled HbA1c -0.84%, bodyweight -2.24 kg and BMI -1.61 kg/m2 versus placebo, with a moderate increase in GI adverse events, and a GLP-1-class network meta-analysis (Vosoughi et al., EClinicalMedicine 2021, 64 RCTs) placed efpeglenatide's weight effect within the class (point estimate -3.2 kg over placebo with a 95% CI of -6.53 to 0.15 that crosses zero, while semaglutide 2.4 mg led at -9.9 kg).
The honest counterweight is decisive on regulatory status: despite this strong cardiorenal dataset, efpeglenatide is INVESTIGATIONAL — it is not FDA-approved or marketed anywhere (its development was not carried through to approval), so it is not a treatment you can be prescribed.
Its proven effects are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — there is NO demonstrated lifespan/healthspan or longevity outcome; framing it as a longevity drug would be reading a cardiovascular/renal endpoint as something it is not.
Adverse effects are class-typical: dose-related gastrointestinal events (nausea, vomiting, diarrhea, constipation, bloating were more frequent than placebo in AMPLITUDE-O and drove some discontinuation), the GLP-1-class thyroid C-cell (medullary carcinoma) warning is expected to apply, and the usual incretin cautions around pancreatitis, gallbladder events, and lean-mass loss alongside fat loss are unresolved by long-term data.
Because it is an investigational drug, grey-market 'efpeglenatide' sold online carries serious identity, purity, sterility, and dosing risks with no clinical oversight. It is an unapproved drug, not a supplement, and is sandboxed out of goal-based and stack recommendations.
An exendin-4 (exenatide-lineage) GLP-1 receptor agonist fused to a human Fc fragment for a long half-life and weekly dosing — mechanistically distinct from the human-GLP-1-based agents (semaglutide, liraglutide). The single upstream target driving all downstream metabolic and cardiorenal effects; AMPLITUDE-O is notable because it proved an exendin-based agonist also lowers cardiovascular events.
Stimulates pancreatic insulin release in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk (few hypoglycemia events in the trials).
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the primary driver of the weight loss seen in the obesity and diabetes trials.
Beyond glucose lowering, efpeglenatide reduced major adverse cardiovascular events and a composite kidney outcome (worsening kidney function / new macroalbuminuria) in AMPLITUDE-O — the GLP-1-class cardiorenal benefit, here demonstrated for an exendin-based agent across the spectrum of baseline kidney disease.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the dose-dependent nausea seen early in treatment.
How Efpeglenatide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Obtaining or using grey-market 'efpeglenatide' means taking an investigational drug with no clinical oversight, dosing standard, or product-quality guarantee. Strongly discouraged.
If you use insulin or an insulin secretagogue, such as a sulfonylurea or meglitinide, adding another glucose-lowering treatment may increase the risk of low blood glucose (hypoglycaemia). Use only under the treating clinical or trial team’s supervision. They should review your medicines, glucose monitoring and whether insulin or secretagogue doses need adjustment. Do not start this treatment or adjust your diabetes medicines yourself.
Expected to be contraindicated — the GLP-1 class carries a thyroid C-cell tumor warning.
Contraindicated — weight loss and an investigational drug are not appropriate in pregnancy or breastfeeding.
GLP-1 agonism slows gastric emptying, which can reduce the rate/extent of absorption of co-administered oral drugs — relevant for time-critical or narrow-therapeutic-index oral medicines.
Combining a glucose-lowering incretin agonist with insulin or sulfonylureas increases hypoglycemia risk; dose reduction of the secretagogue is typically required in supervised use. Efpeglenatide alone showed few hypoglycemia events.
Stacking efpeglenatide with another GLP-1/incretin agonist (semaglutide, liraglutide, dulaglutide, tirzepatide) compounds gastrointestinal toxicity and glucose-lowering with no evidence of added benefit; this combination is not studied and is dangerous.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Tip: We do not know exactly what product you used or how. Follow the urgent advice for your symptom and contact a clinician or pharmacist promptly about the next dose or application. Do not guess a lower dose or change the schedule to continue.
The available source did not grade how severe these reactions were. This does not mean they were mild.
Tip: Class-typical GI effects (more frequent than placebo in AMPLITUDE-O); generally transient and dose-related; a reason for some discontinuation.
Tip: We do not know exactly what product you used or how. Follow the urgent advice for your symptom and contact a clinician or pharmacist promptly about the next dose or application. Do not guess a lower dose or change the schedule to continue.
Tip: Rapid weight loss and incretin-class effects are associated with gallbladder events; report severe abdominal pain.
Tip: A class concern for incretin drugs; discontinue and seek care for persistent severe abdominal pain. Long-term incidence not established.
Efpeglenatide has an evidence score of 4.3/10 — emerging evidence based on 21 indexed studies, including 2 meta-analyses. An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky. Representative study: PMID 34877513.
Dosing for Efpeglenatide: SupStack does not provide a self-directed dosing protocol for Efpeglenatide. A dose used in a clinical trial does not establish a safe consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration.
Timing is flexible for Efpeglenatide — consistent daily use matters more than the time of day. Trials dosed once weekly subcutaneously with gradual dose escalation to limit gastrointestinal effects; the long half-life supports once-weekly administration.
No consumer dose of Efpeglenatide is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Selected serious risks: pancreatitis (class concern). How often they occur is not established for all of them. Reported side effects include treatment discontinuation due to adverse events, gallbladder / biliary events. How often they occur is not established for all of them. Use caution if any of these apply to you: Not a dietary supplement — investigational; do not self-source grey-market vials; Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell precaution, not a product-label contraindication: this investigational drug has no label, and not every approved GLP-1 product carries the US thyroid boxed warning); History of pancreatitis.
What side effects does Efpeglenatide have?Don't take this if…
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Dulaglutide
Too few graded studiesAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 21 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research